Investigating Monocytes in Patients with Atrophic Age-Related Macular Degeneration

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on patients with atrophic age-related macular degeneration (AMD), a leading cause of irreversible blindness. It aims to analyze monocytes collected from these patients to understand their survival and the role of cytokines in the disease process. By examining the inflammatory response in the sub-retinal space, the study seeks to identify specific cytokines that may contribute to the progression of AMD. The findings could pave the way for potential therapeutic strategies for atrophic AMD, which currently lacks effective treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

General criteria:

* Male or female older than 50,
* Provide written informed consent,
* Patient affiliated to French social security,
* Maximum sampling volume (care + research) per 30-day period to be adapted according to the weight of the patient

Specific criteria:

Patient presenting in both eyes:

* Either the same type of AMD defined according to the modified international AREDS study (Ferris et al. 2013),
* or early AMD in one eye and atrophic AMD in the other eye, the patient will therefore be defined as being atrophic
* or early AMD in one eye and exudative AMD in the other eye, the patient will therefore be defined as exudative,
* or no retinal pathology (control group).

Exclusion Criteria:

General criteria:

* Patient whose weight is less than 50kg,
* Adult patient under guardianship or curatorship or unable to express consent,
* Person deprived of liberty,
* Patient participating in an ongoing clinical trial during the inclusion visit,

Specific criteria:

* Patient with atrophic AMD in one eye and exudative AMD in the other eye,
* Patient presenting with chronic retinal pathologies other than AMD, defined according to the modified international AREDS study (Ferris et al. 2013) , in the included eye,
* Patient taking systemic drugs with an immunomodulatory action: immunosuppressants, immunomodulators, chemotherapy or corticosteroids,
* Patient with systemic pathologies modifying their immune status,
* Patient with a history of diabetes,
* Patient who had dynamic phototherapy on the included eye.

Where it's running

• Hôpital Edouard Herriot
  Lyon, France Recruiting
• Service d'ophtalmologie-HOSPICES CIVILS DE LYON - Hôpital de la Croix-Rousse
  Lyon, France Recruiting

Study contacts

• Principal investigator: Thibaud Mathis, MD — Service d'Ophtalmologie Hospices Civils de Lyon Hôpital de la Croix Rousse
• Study coordinator: Thibaud Mathis, MD
• Email: thibaud.mathis@chu-lyon.fr
• Phone: 4 26 10 93 22

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding Age-Related Macular Degeneration and Its Progression

  This study looks at how age-related macular degeneration develops and progresses by comparing people with the condition to healthy individuals, using non-invasive tests and personal feedback.

  Recruiting Center for Eye Research Australia · East Melbourne, Victoria · NCT04739319

• Blepharoptosis After Repeated Anti-VEGF Injections in One Eye

  This study tests whether repeated intravitreal anti-VEGF injections in one eye affect eyelid position compared with the untreated fellow eye.

  Recruiting Fatih Sultan Mehmet Training and Research Hospital · Istanbul · NCT07821450

• First-in-human test of ARO-033 in adults

  This study tests whether ARO-033 is safe and tolerable, and how it behaves in the body, in healthy adults and in adults with age-related macular degeneration.

  Recruiting Phase 1 Arrowhead Pharmaceuticals · Auckland · NCT07662096

• Predicting Risk of AMD Progression Using Imaging in Aging Eyes

  Researchers are test a new screening approach to detect early AMD and monitor its progression in adults 55 and older, to see if personalized monitoring can help in community settings.

  Recruiting at 2 sites Singapore National Eye Centre · Singapore and 1 other locations · NCT07653269

• C.001 for retinal degeneration: a first-in-human dose-escalation safety test

  A first-in-human study will test the safety and tolerability of a single subretinal injection of C.001 in adults with retinal diseases involving retinal pigment epithelium degeneration.

  Recruiting at 2 sites Phase 1 Cellio Therapeutics Inc · Beverly Hills, California and 2 other locations · NCT07594236

• Central microperimetry and radial OCT in geographic atrophy

  We will test whether central microperimetry and radial OCT scans can more accurately measure how geographic atrophy progresses toward the fovea in people with or at risk for GA from age-related macular degeneration.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07556406

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.